Randomized Controlled Trials of Electronic Health Record Interventions: Design, Conduct, and Reporting Considerations.


Journal

Annals of internal medicine
ISSN: 1539-3704
Titre abrégé: Ann Intern Med
Pays: United States
ID NLM: 0372351

Informations de publication

Date de publication:
02 06 2020
Historique:
entrez: 2 6 2020
pubmed: 2 6 2020
medline: 1 12 2020
Statut: ppublish

Résumé

Electronic health record (EHR) systems can be configured to deliver novel EHR interventions that influence clinical decision making and to support efficient randomized controlled trials (RCTs) designed to evaluate the effectiveness, safety, and costs of those interventions. In designing RCTs of EHR interventions, one should carefully consider the unit of randomization (for example, patient, encounter, clinician, or clinical unit), balancing concerns about contamination of an intervention across randomization units within clusters (for example, patients within clinical units) against the superior control of measured and unmeasured confounders that comes with randomizing a larger number of units. One should also consider whether the key computational assessment components of the EHR intervention, such as a predictive algorithm used to target a subgroup for decision support, should occur before randomization (so that only 1 subgroup is randomized) or after randomization (including all subgroups). When these components are applied after randomization, one must consider expected heterogeneity in the effect of the differential decision support across subgroups, which has implications for overall impact potential, analytic approach, and sample size planning. Trials of EHR interventions should be reviewed by an institutional review board, but may not require patient-level informed consent when the interventions being tested can be considered minimal risk or quality improvement, and when clinical decision making is supported, rather than controlled, by an EHR intervention. Data and safety monitoring for RCTs of EHR interventions should be conducted to guide institutional pragmatic decision making about implementation and ensure that continuing randomization remains justified. Reporting should follow the CONSORT (Consolidated Standards of Reporting Trials) Statement, with extensions for pragmatic trials and cluster RCTs when applicable, and should include detailed materials to enhance reproducibility.

Identifiants

pubmed: 32479183
doi: 10.7326/M19-0877
doi:

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

S85-S91

Subventions

Organisme : NCATS NIH HHS
ID : UL1 TR000004
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR001872
Pays : United States

Auteurs

Mark J Pletcher (MJ)

University of California, San Francisco, San Francisco, California (M.J.P., V.F., N.N., S.P., R.J.R., A.H., A.R., R.J.C., C.E.M., R.G., A.A.).

Valerie Flaherman (V)

University of California, San Francisco, San Francisco, California (M.J.P., V.F., N.N., S.P., R.J.R., A.H., A.R., R.J.C., C.E.M., R.G., A.A.).

Nader Najafi (N)

University of California, San Francisco, San Francisco, California (M.J.P., V.F., N.N., S.P., R.J.R., A.H., A.R., R.J.C., C.E.M., R.G., A.A.).

Sajan Patel (S)

University of California, San Francisco, San Francisco, California (M.J.P., V.F., N.N., S.P., R.J.R., A.H., A.R., R.J.C., C.E.M., R.G., A.A.).

Robert J Rushakoff (RJ)

University of California, San Francisco, San Francisco, California (M.J.P., V.F., N.N., S.P., R.J.R., A.H., A.R., R.J.C., C.E.M., R.G., A.A.).

Ari Hoffman (A)

University of California, San Francisco, San Francisco, California (M.J.P., V.F., N.N., S.P., R.J.R., A.H., A.R., R.J.C., C.E.M., R.G., A.A.).

Andrew Robinson (A)

University of California, San Francisco, San Francisco, California (M.J.P., V.F., N.N., S.P., R.J.R., A.H., A.R., R.J.C., C.E.M., R.G., A.A.).

Russell J Cucina (RJ)

University of California, San Francisco, San Francisco, California (M.J.P., V.F., N.N., S.P., R.J.R., A.H., A.R., R.J.C., C.E.M., R.G., A.A.).

Charles E McCulloch (CE)

University of California, San Francisco, San Francisco, California (M.J.P., V.F., N.N., S.P., R.J.R., A.H., A.R., R.J.C., C.E.M., R.G., A.A.).

Ralph Gonzales (R)

University of California, San Francisco, San Francisco, California (M.J.P., V.F., N.N., S.P., R.J.R., A.H., A.R., R.J.C., C.E.M., R.G., A.A.).

Andrew Auerbach (A)

University of California, San Francisco, San Francisco, California (M.J.P., V.F., N.N., S.P., R.J.R., A.H., A.R., R.J.C., C.E.M., R.G., A.A.).

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH